Secondary analyses included alternative assessments of clinical and diary pain scores , scores on quality-of-life tests ( the European Organization for Research and Treatment of Cancer [ EORTC-QLQ-C30 ] , Quality of Life Questionnaire-Pancreatic modification [ QLQ-PAN28 ] , European Quality of Life questionnaire [ EuroQOL EQ-5D ] , and European Quality of Life questionnaire - Visual Analog Score [ EQ-VAS ] ) , levels of antioxidants , use of opiates , and adverse events .
